Using a blended candle approach, one can see that the sentiment for PIRS is setting up for a squeeze. The volume is contracting over the past few weeks since beginning of the year. Bollinger band is showing signs of a squeeze. ATR (14) is showing lowest volatility over the past 100 day period. The Blended candles offer summation of short term (20 day) and medium...
Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS):
AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments
Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments
Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments
SGEN Seagen 35Mil upfront payment and...
PIRS Pieris Pharmaceuticals has collaboration agreements with AstraZeneca, Boston Pharmaceuticals, Servier, Seagen and Genentech, part of Roche.
AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments
Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments
Genentech member of RHHBY Roche Group 20Mil upfront...
-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology.
-PIRS went on to explain that the collaboration will enable it...
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
1. The 50 MA is about to cross golden over the 200 MA on the daily
2. Bullish engulfing on the daily
3. Multiple golden crosses on the weekly
Go long and prosper!
Pieris is in an upward channel and looking bullish. Analyst ratings on the stocks aren't great, but Zacks has given it a HUGE Earnings Surprise Prediction (13.25%!), which should help the stock continue its run until the next report date in early August. Be aware, however, that it is approaching some stiff resistance above $4.60. It should rise Monday, but then it...
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. The company's clinical pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases,...
Upgrades galore for NASDAQ:PIRS lately as analysts see great upside potential for the company. Most recently PIRS presented data from a phase 1 study on its new technology ANTICALIN which it is developing in collaboration with NYSE:AZN was released and commented on by the Chief development officer. "We are encouraged by the safety and tolerability of...
